DESTINY-Breast03 Phase 3 Study Results
Drug-Related TEAEs in ≥20% of Patients
Nausea 73
Fatiguea
48
Alopecia
Vomiting
Neutropeniab
Anemiac
Decreased appetite
Thrombocytopeniad
Transaminases increasede
Leukopenia
Diarrhea
Constipation
5 0
24
5
42
38
34
34
33
33
33
29
29
24
24
14
8
8
5
00
10 10
2 1
5
16
1 9
80
60
40
33
33
41
51
23
23
24
24
3
8
23
23
23
22
6
19
31
22
1
2
18
21
00
13
20
0
20
40
60
10
Daiichi-Sankyo
DESTINY-Breast04
T-DXd, Any Grade
T-DXd, Grade ≥3
TPC, Any Grade
TPC, Grade ≥3
80
80
60
Patients Experiencing Drug-Related TEAE (%)
T-DXd, trastuzumab deruxtecan; TEAE, treatment-emergent adverse event; TPC, treatment of physician's choice.
*This category includes the preferred terms fatigue, asthenia, and malaise. "This category includes the preferred terms neutrophil count decreased and neutropenia. This category includes the preferred terms hemoglobin decreased, red-cell count
decreased, anemia, and hematocrit decreased. This category includes the preferred terms platelet count decreased and thrombocytopenia. "This category includes the preferred terms transaminases increased, aspartate aminotransferase increased,
alanine aminotransferase increased, gamma-glutamyltransferase increased, liver function test abnormal, hepatic function abnormal. This category includes the preferred terms white-cell count decreased and leukopenia.
ASCO 2022 #LBA3 Plenary Session
18View entire presentation